Association of opioid and benzodiazepine coprescribing with adverse events among older adults with cancer
JNCI: Journal of the National Cancer Institute · 2025
DOI: 10.1093/jnci/djaf072 ↗Kurz gefasst
Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2025. Verfasst von Devon K Check und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, United States. Hauptthemen laut MEDLINE: Analgesics, Opioid, Benzodiazepines, Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIDA NIH HHS, AstraZeneca.
Abstract (Originalsprache)
Background
Many older adults with cancer are coprescribed opioids/benzodiazepines; evidence on harms is lacking.
Methods
Using SEER-Medicare (2012-2019), we identified patients with breast, colorectal, or lung cancer. Cox proportional hazards models estimated the adjusted hazard ratios (HRs) of coprescribing (measured from claims, at the day level) with the immediate risk of overdose, fall/fracture, and all-cause hospitalization. In a secondary analysis, models were stratified by ≥90 days of continuous medication supply.
Results
In our cohort of 107 288 patients, compared with those prescribed neither medication, those prescribed benzodiazepines had an increase in the immediate risk of falls/fractures (HR = 1.17, 95% CI = 1.02 to 1.34) and all-cause hospitalizations (HR = 1.08, 95% CI = 1.04 to 1.12). Patients prescribed opioids had an increase in the immediate risk of overdose (HR = 5.62, 95% CI = 4.86 to 5.62), falls/fractures (HR = 1.56, 95% CI = 1.41 to 1.73), and all-cause hospitalizations (HR = 1.26, 95% CI = 1.23 to 1.30). HRs were similar for patients coprescribed opioids/benzodiazepines. For patients without continuous exposure to 1 or both medications, effects were larger for coprescribed opioids/benzodiazepines vs opioids for overdose (HR = 15.22, 95% CI = 8.79 to 26.35 vs HR = 6.85, 95% CI = 6.85 to 26.35) and all-cause hospitalization (HR = 3.21, 95% CI = 2.60 to 3.96 vs HR = 1.98, 95% CI = 1.87 to 2.10).
Conclusions
Overall, compared with no prescribing, benzodiazepine prescribing and opioid prescribing were each associated with an increase in the immediate risk of adverse events. Effects were similar for those prescribed opioids and those coprescribed opioids/benzodiazepines. For patients with intermittent vs long-term medication exposure, coprescribing additionally increased the risk of overdose and all-cause hospitalization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, United States.
- Duke Cancer Institute, Duke University, Durham, NC, United States.
- Center for the Study of Aging and Human Development, Duke University School of Medicine, Durham, NC, United States.
- New England Geriatric Research Education and Clinical Center, VA Boston Healthcare System, Boston, MA, United States.
- Harvard Medical School, Harvard University, Boston, MA, United States.
- Department of Pharmacy Systems, Outcomes, and Policy, College of Pharmacy, University of Illinois Chicago, Chicago, IL, United States.
ORCID-Profile: Devon K Check, Andrea Des Marais, Katie F Jones, Charles E Gaber, Jessica S Merlin, Amy O'Regan, Nicole Fergestrom, Lauren E Wilson, Aaron N Winn
Förderung
- NCI NIH HHS
- NIDA NIH HHS
- AstraZeneca
- NIA NIH HHS
- NIH
- National Institute on Aging
- National Institute on Drug Abuse
Zitieren
APA
Check, D. K., Soneji, S., Cohen, H. J., Des Marais, A., Jones, K. F., Gaber, C. E., Merlin, J. S., O'Regan, A., Fergestrom, N., Wilson, L. E., & Winn, A. N. (2025). Association of opioid and benzodiazepine coprescribing with adverse events among older adults with cancer. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djaf072
Vancouver
Check DK, Soneji S, Cohen HJ, Des Marais A, Jones KF, Gaber CE, et al. Association of opioid and benzodiazepine coprescribing with adverse events among older adults with cancer. JNCI: Journal of the National Cancer Institute. 2025. doi:10.1093/jnci/djaf072
BibTeX
@article{Check2025,
author = {Check, Devon K and Soneji, Samir and Cohen, Harvey Jay and Des Marais, Andrea and Jones, Katie F and Gaber, Charles E and Merlin, Jessica S and O'Regan, Amy and Fergestrom, Nicole and Wilson, Lauren E and Winn, Aaron N},
title = {Association of opioid and benzodiazepine coprescribing with adverse events among older adults with cancer},
journal = {JNCI: Journal of the National Cancer Institute},
year = {2025},
doi = {10.1093/jnci/djaf072}
}
EUVIMED